Literature DB >> 18212106

Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.

Alexis Soummer, Armelle Mathonnet, Olivier Scatton, Pierre Philippe Massault, André Paugam, Virginie Lemiale, Jean Paul Mira, Eric Dannaoui, Alain Cariou, Olivier Lortholary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18212106      PMCID： PMC2292512          DOI： 10.1128/AAC.01611-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

1.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

2.  Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.

Authors:  Caitlin Reed; Ashraf Ibrahim; John E Edwards; Irwin Walot; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

Review 3.  [Vasculitis secondary to fungal infections].

Authors:  Valérie Zeller; Olivier Lortholary
Journal:  Presse Med       Date:  2004-11-06       Impact factor: 1.228

4.  Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Valentina Avanessian; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Deferiprone iron chelation as a novel therapy for experimental mucormycosis.

Authors:  Ashraf S Ibrahim; John E Edwards; Yue Fu; Brad Spellberg
Journal:  J Antimicrob Chemother       Date:  2006-08-23       Impact factor: 5.790

6.  Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.

Authors:  Brad Spellberg; Yue Fu; John E Edwards; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 7.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

8.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  In vitro susceptibilities of zygomycetes to conventional and new antifungals.

Authors:  Eric Dannaoui; Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

10.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebermariam; Yue Fu; Lin Lin; Mohamed I Husseiny; Samuel W French; Julie Schwartz; Christopher D Skory; John E Edwards; Brad J Spellberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
  10 in total
  8 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

3.  Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

Authors:  Brad Spellberg; David Andes; Mario Perez; Anne Anglim; Hector Bonilla; Glenn E Mathisen; Thomas J Walsh; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

Review 4.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

5.  Antibacterial activities of iron chelators against common nosocomial pathogens.

Authors:  Mitchell G Thompson; Brendan W Corey; Yuanzheng Si; David W Craft; Daniel V Zurawski
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

6.  Tumor shape pulmonary mucormycosis associated with sinonasal aspergillosis in a diabetic patient.

Authors:  Sophie Point; Frédéric Gabriel; Hugues Bégueret; Jacques Jougon; Fanny Lanternier; Frédéric Grenouillet; Manal Abdel Fattah; Emilie Catherinot; Chantal Raherison; Elodie Blanchard
Journal:  Med Mycol Case Rep       Date:  2017-09-01

7.  Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Authors:  Dounia Bitar; Dieter Van Cauteren; Fanny Lanternier; Eric Dannaoui; Didier Che; Francoise Dromer; Jean Claude Desenclos; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

8.  Pharmacological iron-chelation as an assisted nutritional immunity strategy against Piscirickettsia salmonis infection.

Authors:  Mario Caruffo; Dinka Mandakovic; Madelaine Mejías; Ignacio Chávez-Báez; Pablo Salgado; Daniela Ortiz; Liliana Montt; Javiera Pérez-Valenzuela; Francisca Vera-Tamargo; José Manuel Yánez; Jurij Wacyk; Rodrigo Pulgar
Journal:  Vet Res       Date:  2020-10-28       Impact factor: 3.683
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.